Intranasal deferoxamine engages multiple pathways to decrease memory loss in the APP/PS1 model of amyloid accumulation

Neuroscience Letters

Volumn 584, Issue , 2015, Pages 362-367

  Fine, Jared M ^a   Renner, Daniel B ^a   Forsberg, Anna C ^a   Cameron, Rachel A ^a   Galick, Benjamin T ^a   Le, Clint ^a   Conway, Patrick M ^a   Stroebel, Benjamin M ^a   Frey, William H ^a   Hanson, Leah R ^a  

^a REGIONS HOSPITAL   (United States)

Author keywords

Alzheimer's disease; Glycogen synthase kinase; Intranasal; Malondialdehyde; Oxidative stress; Radial arm water maze

Indexed keywords

AMYLOID; BETA CATENIN; DEFEROXAMINE MESYLATE; GLIAL FIBRILLARY ACIDIC PROTEIN; GLYCOGEN SYNTHASE KINASE 3BETA; MALONALDEHYDE; SYNAPTOPHYSIN; AMYLOID PRECURSOR PROTEIN; DEFEROXAMINE; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; IRON CHELATING AGENT; PRESENILIN 1;

ALZHEIMER DISEASE; AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; BRAIN CORTEX; BRAIN TISSUE; CONTROLLED STUDY; DRUG MECHANISM; HIPPOCAMPUS; LOCOMOTION; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; REFERENCE MEMORY; SENSORIMOTOR FUNCTION; WORKING MEMORY; ANIMAL; DRUG EFFECTS; GENETICS; INTRANASAL DRUG ADMINISTRATION; LONG TERM MEMORY; MEMORY DISORDERS; METABOLISM; PSYCHOLOGY; SHORT TERM MEMORY; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

ADMINISTRATION, INTRANASAL; ALZHEIMER DISEASE; AMYLOID; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BETA CATENIN; DEFEROXAMINE; GLYCOGEN SYNTHASE KINASE 3; IRON CHELATING AGENTS; MALE; MEMORY DISORDERS; MEMORY, LONG-TERM; MEMORY, SHORT-TERM; MICE, TRANSGENIC; OXIDATIVE STRESS; PRESENILIN-1; SIGNAL TRANSDUCTION;

EID: 84910623451     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2014.11.013     Document Type: Article

References (26)

1. Skaper S.D. Alzheimer's disease and amyloid: culprit or coincidence?. Int. Rev. Neurobiol. 2012, 102:277-316.
2. Gao C., et al. New animal models of Alzheimer's disease that display insulin desensitization in the brain. Rev. Neurosci. 2013, 24(6):607-615.
3. Raven E.P., et al. Increased iron levels and decreased tissue integrity in hippocampus of Alzheimer's disease detected in vivo with magnetic resonance imaging. J. Alzheimer's Dis. 2013.
4. Ayton S., Lei P., Bush A.I. Metallostasis in Alzheimer's disease. Free Radical Biol. Med. 2013, 62:76-89.
5. de Lima M.N., et al. Reversion of age-related recognition memory impairment by iron chelation in rats. Neurobiol. Aging 2008, 29(7):1052-1059.
6. Crapper McLachlan D.R., et al. Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet 1991, 337(8753):1304-1308.
7. Fine J.M., et al. Intranasal deferoxamine improves performance in radial arm water maze: stabilizes HIF-1alpha, and phosphorylates GSK3beta in P301L tau transgenic mice. Exp. Brain Res. 2012, 219(3):381-390.
8. Hanson L., et al. Intranasal delivery of deferoxamine reduces spatial memory loss in APP/PS1 mice. Drug Delivery Transl. Res. 2012, 1-9.
9. Febbraro F., et al. Chronic intranasal deferoxamine ameliorates motor defects and pathology in the alpha-synuclein rAAV Parkinson's model. Exp. Neurol. 2013, 247C:45-58.
10. Fine J.M., et al. Intranasally-administered deferoxamine mitigates toxicity of 6-OHDA in a rat model of Parkinson's disease. Brain Res. 2014, 1574:96-104.
11. Arendash G.W., et al. Multi-metric behavioral comparison of APPsw and P301L models for Alzheimer's disease: linkage of poorer cognitive performance to tau pathology in forebrain. Brain Res. 2004, 1-2:29-41. 1012.
12. Hanson L.R., et al. Intranasal administration of CNS therapeutics to awake mice. J. Visualized Exp. 2013, 74.
13. Kamphuis W.et al. GFAP isoforms in adult mouse brain with a focus on neurogenic astrocytes and reactive astrogliosis in mouse models of Alzheimer disease. PLoS One 2012, 7(8):e42823.
14. Cai Z., Zhao Y., Zhao B. Roles of glycogen synthase kinase 3 in Alzheimer's disease. Curr. Alzheimer Res. 2012, 9(7):864-879.
15. Petit-Paitel A. GSK-3beta: a central kinase for neurodegenerative diseases?. Med. Sci. 2010, 26(5):516-521. (Paris).
16. Kapoor S. Deferoxamine: emerging, new neuro-protective benefits. Neurol. Sci. 2013, 34(2):562-575.
17. Aghdam S.Y., Barger S.W. Glycogen synthase kinase-3 in neurodegeneration and neuroprotection: lessons from lithium. Curr. Alzheimer Res. 2007, 4(1):21-31.
18. Zhu X., et al. Causes of oxidative stress in Alzheimer disease. Cell. Mol. Life Sci. 2007, 64(17):2202-2210.
19. Del Rio D., Stewart A.J., Pellegrini N. A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress. Nutr. Metab. Cardiovasc. Dis. 2005, 15(4):316-328.
20. Bariskaner H., et al. Effects of deferoxamine on tissue lactate and malondialdehyde levels in cerebral ischemia. Methods Findings Exp. Clin. Pharmacol. 2003, 25(5):371-376.
21. Dinc C., et al. Comparison of deferoxamine and methylprednisolone: protective effect of pharmacological agents on lipid peroxidation in spinal cord injury in rats. Spine (Phila Pa 1976) 2013, 38(26):E1649-E1655.
22. Arent C.O., et al. Synergist effects of n-acetylcysteine and deferoxamine treatment on behavioral and oxidative parameters induced by chronic mild stress in rats. Neurochem. Int. 2012, 61(7):1072-1080.
23. Tonin A.M., et al. Long-chain 3-hydroxy fatty acids accumulating in LCHAD and MTP deficiencies induce oxidative stress in rat brain. Neurochem. Int. 2010, 56(8):930-936.
24. Domingo J.L. Aluminum and other metals in Alzheimer's disease: a review of potential therapy with chelating agents. J. Alzheimer's Dis. 2006, 10(2-3):331-341.
25. Guo C., et al. Intranasal deferoxamine reverses iron-induced memory deficits and inhibits amyloidogenic APP processing in a transgenic mouse model of Alzheimer's disease. Neurobiol. Aging 2012, 34(2):562-575.
26. Eckert A., Schmitt K., Gotz J. Mitochondrial dysfunction - the beginning of the end in Alzheimer's disease? Separate and synergistic modes of tau and amyloid-beta toxicity. Alzheimer's Res. Ther. 2011, 3(2):15.